Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may uncover immune clues in lingering illnesses

NCT ID NCT06731179

Knowledge-focused Sponsor: ViraxBio Labs Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for people with Long COVID, Lyme disease, or ME/CFS (chronic fatigue syndrome). Researchers want to see if a special blood test can find problems with T-cells, which are part of the immune system. Participants will give blood samples and fill out symptom questionnaires at the start and after 6 months. No treatments are given—this is just to learn more about these conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Up to 120 male and female participants identified as having persistent symptoms associated with a diagnosis of long COVID, PTLDS or ME/CFS. Additionally, up to 40 healthy male and female who have not been clinically diagnosed as having symptoms associated with long COVID, PTLDS or ME/CFS will be enrolled as a control group.

Ages

15 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Persistent symptoms for groups 1-3 for consistency. Inclusion Criteria: 1. Aged 18 years or older 2. History of acute COVID-19 infection (medically recorded) 3. Symptoms of fatigue and, shortness of breath and/or, joint pain and/or, problems with memory and concentration which have been present for more than a period of 6 months post infection 4. Nonsteroidal anti-inflammatory drugs (NSAIDs such as ibuprofen, diclofenac, aspirin, etc.) must have been stopped at least 48 hours prior to admission to the clinical research centre (evaluation through questionnaire). 5. Willing and able to sign the ICF and comply with study procedures. Exclusion Criteria: 1. Taking immunosuppressive medication (including corticosteroids), or receiving chemotherapy, cytokine or anti-cytokine therapy, or antithrombotic medication (evaluation through questionnaire). 2. Significant and/or acute illness within 5 days prior to admission that may impact safety assessments, in the opinion of the Investigator. 3. Participants who are, in the opinion of the Investigator, not suitable for enrolment for another reason. For example, participants with: cognitive impairment or severe mental health conditions that might affect their ability to provide informed consent or follow study procedures; non-adherence risk where participants are unlikely to follow study protocols; participants with other chronic inflammatory conditions not under investigation e.g. inflammatory bowel disease, COPD that may have immune profiles that differ from the study's intended populationI

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Long COVID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

long COVID-19 myalgic encephalomeyelitis/chronic fatigue syndrome post-treatment Lyme disease syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Long COVID Myalgic encephalomyelitis/chronic fatigue syndrome (me/CFS) (icd-10 G93.3) PTLDS

Contacts and locations

Locations

  • Glasgow and Clyde NHS

    Glasgow, United Kingdom

  • Monklands University Hospital, NHS

    Airdrie, United Kingdom

  • Raigmore Hospital, Inverness

    Inverness, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.